Methylphenidate half-life
The three-hour input describes parent methylphenidate elimination, not the release duration of an extended-release tablet.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.
Methylphenidate: evidence and interpretation notes
What the curve is actually following
The three-hour input describes parent methylphenidate elimination, not the release duration of an extended-release tablet. Product engineering can spread absorption while the molecule’s elimination half-life remains comparatively short.
The calculator follows Methylphenidate with a 3-hour half-life. That simplification is useful for curve shape and comparison, but it is not an individualized pharmacokinetic estimate.
Methylphenidate is a stimulant where formulation is central. Immediate-release and extended-release products can have different concentration-time profiles even when the elimination concept is similar.
The 3 hour value is a simple parent-drug input for the calculator. It does not capture release technology, symptom response, or clinical dosing intervals.
The citations use a direct extended-release DailyMed label and the compound record.
This page does not provide ADHD treatment guidance or medication timing advice.
For Methylphenidate, persistence in the model should be separated from alertness, euphoria, appetite change, sleep disruption, and cardiovascular effects. Those outcomes can diverge from parent-drug decline.
What each source contributes
- DailyMed: Methylphenidate hydrochloride extended-release tablet. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- PubChem: Methylphenidate. This identity record confirms names and compound identity and does not supply a human half-life.
For Methylphenidate, the numerical model is tied most closely to DailyMed: Methylphenidate hydrochloride extended-release tablet. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.
Why there is no range on the chart
This profile plots 3 hours for Methylphenidate without adding an unsourced high-low band. A single supported center is more honest than manufacturing a range from unrelated routes, populations, or formulations.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 3 h as a representative input for Methylphenidate. In the simplified model, about 0.4% remains after 24 hours and about 3% remains after five half-lives, or roughly 15 h.
This is a short curve. The modeled amount changes noticeably over the same day, while effects, metabolites, and safety questions can still follow a different timeline. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
stimulant context
Stimulant half-life estimates can shift with urine pH, enzyme activity, formulation, dose, and whether metabolites are measured separately.
- Alertness or subjective stimulation can end before modeled elimination.
- Sleep disruption and downstream effects are not represented by the curve.
- Formulation and route can change peak timing without changing the displayed model.
ComparisonTimeline checkpoints and nearby profiles
Methylphenidate timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 6 h | 25.0% | Long-tail portion of the model |
| 12 h | 6.25% | Low modeled remainder, not a clearance guarantee |
| 24 h | 0.39% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Methylphenidate within the stimulant group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Caffeine (5 h)
- Mephedrone (2.0 h)
- Amphetamine (11 h)
- Nicotine (2 h)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 3 h |
|---|---|
| Curve type | Normalized, first-order decline |
Selection note: The three-hour input describes parent methylphenidate elimination, not the release duration of an extended-release tablet. Product engineering can spread absorption while the molecule’s elimination half-life remains comparatively short.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: Methylphenidate hydrochloride extended-release tablet.Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Identity record PubChem Compound Summary: Methylphenidate.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the stimulant group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.